{
  "docId": "019de074-a4f4-74e1-8870-171c8951fea8",
  "docSlug": "e0247ed9fbf6e59fd6aeeea6f3eacc2d",
  "documentTitle": "23andMe | Investor Presentation Deck | 57 slides",
  "authorId": "23andme",
  "authorName": "23andMe",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2023-04-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 45,
  "pageCount": 57,
  "prevPage": 44,
  "nextPage": 46,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a process flow diagram to illustrate the study design (Part A to Part B).",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de074-a4f4-74e1-8870-171c8951fea8/45",
  "deckHref": "/decks/019de074-a4f4-74e1-8870-171c8951fea8",
  "deckJsonHref": "/decks/019de074-a4f4-74e1-8870-171c8951fea8.json",
  "deckAnchorHref": "/decks/019de074-a4f4-74e1-8870-171c8951fea8#slide-45",
  "components": [
    {
      "bbox": {
        "h": 0.6,
        "w": 0.45,
        "x": 0.05,
        "y": 0.25
      },
      "kind": "diagram",
      "text": "Study Design flow from patient criteria to Part A and Part B cohorts",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "37bddfd0-13dd-4967-8405-3c94d7b50003",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.65,
        "x": 0.05,
        "y": 0.92
      },
      "kind": "disclaimer",
      "text": "Abbreviations: AEs: Adverse Events; DLT: Dose limiting toxicity; DOR: duration of response; IV: intravenous; ORR: Objective Response Rate; OS: Overall Survival; PFS: Progression Free Survival; Q3W: every three weeks; RECIST: Response Evaluation Criteria in Solid Tumors; RP2D: Recommended Phase 2 Dose",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4272ffd2-2c35-496c-b22d-bac5ae01c999",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.43,
        "x": 0.52,
        "y": 0.25
      },
      "kind": "list",
      "text": "Objectives: Primary (Safety, Efficacy) and Secondary/Exploratory (Efficacy, PK, PD)",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e0e5f82f-a93a-4237-a1ae-94eddab28bc3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.1,
        "w": 0.7,
        "x": 0.15,
        "y": 0.05
      },
      "kind": "title",
      "text": "Phase 1/2a Study of 23ME’610 in Patients with Locally Advanced or Metastatic Solid Malignancies",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2062993e-cb1f-49ef-a41e-d3efb0d960f8",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "clinical-trial-design",
      "slug": null,
      "matchId": "22f1f4ba-796d-4949-b06d-16b6190016fe",
      "evidence": "Standard pharmaceutical study design layout",
      "confidence": 0.9
    }
  ],
  "arcBeats": [],
  "loops": [
    {
      "to": 48,
      "from": 36,
      "name": "Quick Win Big Bet",
      "slug": "47-quick-win-big-bet",
      "bestFor": "Transformation planning, 100-day plans, resource allocation",
      "matchId": "25bf5fec-1759-4ae6-8d05-5ad619b628ea",
      "evidence": "The deck presents 23andMe's research and development pipeline and its immuno-oncology programs",
      "position": 2,
      "objective": "What are the opportunities for 23andMe in therapeutics development?",
      "structure": "The Full List -> Quick Wins (Low effort, High impact) -> Big Bets (High effort, High impact) -> Sequenced Roadmap",
      "confidence": 0.6,
      "description": "Separate initiatives into immediate wins and longer-term strategic bets"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}